Allspring Global Investments Holdings LLC Has $37.81 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Allspring Global Investments Holdings LLC reduced its position in Repligen Co. (NASDAQ:RGEN) by 8.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 254,054 shares of the biotechnology company’s stock after selling 24,164 shares during the period. Allspring Global Investments Holdings LLC owned 0.45% of Repligen worth $37,808,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Andra AP fonden acquired a new stake in Repligen in the second quarter worth about $25,000. International Assets Investment Management LLC acquired a new stake in shares of Repligen during the 2nd quarter worth approximately $33,000. UMB Bank n.a. raised its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on RGEN shares. Benchmark reiterated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, UBS Group reduced their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

Shares of RGEN stock opened at $144.14 on Wednesday. The company has a market capitalization of $8.07 billion, a P/E ratio of -3,602.60, a price-to-earnings-growth ratio of 4.24 and a beta of 0.95. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company’s 50 day moving average price is $144.70 and its two-hundred day moving average price is $147.71.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 EPS. On average, analysts expect that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.